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The objective of this study was to evaluate the synergistic activity of Bacopa monniera
with Rivastigmine against aluminum-chloride (AlCl3)-induced cognitive impairment in
rats. Adult male Wistar rats were divided into ten groups (nZ 10) and subjected to their
assigned treatments for 42 days. On the 20th day of the respective drug treatments, all
the animals were trained in the Morris water maze (retention latency) and the elevated
plus maze (transfer latency). After the initial training, the retention latency (RL) and the
transfer latency (TL) were evaluated on the 21st and the 42nd days of the study. Chronic
administration of AlCl3 caused significant memory impairment associated with increased
RL in the Morris water maze task and increased TL in the elevated plus maze test. Inter-
estingly, animals treated with oral administration of B. monniera (100 and 200 mg/kg),
Rivastigmine (5 mg/kg) or a combination of B. monniera (100 mg/kg) with Rivastigmine
(5 mg/kg) showed significant protection against AlCl3-induced memory impairment
compared to animal treated with AlCl3 per se. Additionally, the neuroprotective effect
of B. monniera (100 and 200 mg/kg) was significantly improved when supplemented with
Rivastigmine (5 mg/kg). These findings suggest that treatment with a combination of
B. monniera with Rivastigmine may be highly beneficial compared to their per-se




Synergistic Effect of Bacopa monniera and rivastigmine 2091. Introduction standard isolation cages under standard environmentalDeveloping effective and safe therapeutic treatment stra-
tegies for cognitive disorders, such as amnesia, attention
deficit hyperactivity disorder, and Alzheimer’s disease (AD),
remains a challenge in the field of medicine [1]. The patho-
logical hallmarks of cognitive disorders are memory loss and
learning deficits. Environmental factors have been suggested
as one of the possible contributory causes to the develop-
ment of neurological disorders [2]. In this context, long-term
consumption/exposure to aluminum is also thought to be a
causative factor in the pathogenesis of AD [3]. Exposure to
aluminum is not usually harmful and is not inherently toxic.
However, a high concentration of aluminum is found in peo-
ple with Parkinson’s disease, senile dementia, amyotrophic
lateral sclerosis, and senile dementia associated with AD [4].
Aluminum is a well-known neurotoxicant reported to
accelerate oxidative damage to biomolecules. It crosses the
bloodebrain barrier through the high affinity transferrin re-
ceptors [5] and: (1) causes proteinmisfolding; (2) causes self-
aggregation of highly phosphorylated cytoskeletal proteins,
such as neurofilaments, microtubule-associated proteins,
andamyloid-b; and (3) inhibits slowand fast axonal transports
by damaging synaptic architecture, and induces neuro-
inflammation [6]. Additionally, aluminum is a potent chol-
inotoxin that causes apoptotic neuronal loss and also impairs
hippocampal long-term potentiation. All these neurological
perturbances ultimately result in learning and memory defi-
cits in animals and humans. Further, aluminum has been re-
ported to be found in both senile plaques and neurofibrillary
tangle-bearing neurons in the brains of patients with AD [7].
In the context of treating cognition and related disorders,
plant-basedmedicineshavebeenused in folkmedicine. Some
medicinal plants have been scientifically proven to possess
potent cognition-enhancing properties [8,9]. Bacopa mon-
nieraof the family Scrophulariaceae is awell knowncognitive
enhancer in the Indian system of traditional medicine [10]. It
is also referred to as Herpestis monniera and is commonly
called Brahmi [11]. B. monniera was traditionally used as a
brain (nerve) tonic to enhance memory, learning, and con-
centration. It has been scientifically proven to possess anti-
inflammatory [12], analgesic [13], antipyretic [14], sedative
[15], antiepileptic [16], anxiolytic [14], antidepressant [17],
and antioxidant properties [18].
Studies have reported that B. monniera has anticholines-
terase activity (aids learning and memory skills), and adap-
togenic and antidepressant activity in both acute and chronic
stress situations [19]. It has alsobeen shown tobebeneficial in
reversing scopolamine-inducedoxidative stress anddementia
in experimental animals [10,14,19]. In light of this, the pre-
sent study was conducted to evaluate the possible synergistic
activity of B. monniera with rivastigmine in reversing AlCl3-
induced learning deficits and memory loss in rats.2. Materials and methods
2.1. Animals
Inbred adult male albino Wistar rats (180e200 g body
weight) were used for the study. Animals were housed inconditions with a temperature of 22  2 C, relative hu-
midity of 60  5% and a 12 hour lightedark cycle. Rats were
allowed free access to water and standard laboratory rat
chow (Provimi Animal Nutrition India Pvt Ltd, Bangalore,
India).2.2. Ethics approval
All the experimental protocols were approved by the
Institutional Animal Ethics Committee (IAEC) of The Hima-
laya Drug Company and were conducted according to the
guidelines of the Committee for the Purpose of Control and
Supervision of Experimentation on Animals (CPCSEA), India.2.3. Chemicals and reagents
B. monniera (Bacopa) granules (The Himalaya Drug Com-
pany, Bangalore, India) and rivastigmine (Sun Pharmaceu-
ticals Ltd, Mumbai, India) were used for the study; all other
chemicals and reagents were of analytical grade (HiMedia
Laboratories Pvt Ltd, Mumbai, India).2.4. Experimental protocol
One hundred male Wistar albino rats were randomized into
10 groups (G1eG10), each with 10 animals. The animals in
G1 were treated with vehicle and served as controls. Ani-
mals in G2 and G7 were treated with 5 mg/kg rivastigmine
p.o., G3 and G8 with 100 mg/kg B. monniera p.o., G4 and
G9 with 200 mg/kg B. monniera p.o., and G5 and G10 with a
combination of 5 mg/kg rivastigmine and 100 mg/kg B.
monniera p.o. Along with their assigned drug treatments,
the animals in G7, G8, G9, and G10 were challenged with
AlCl3 (100 mg/kg p.o.) daily for 42 days to induce learning
deficits and amnesia; animals in G6 served as positive
controls and only received AlCl3.
A flow chart of the experimental protocol is shown in
Fig. 1.2.5. Assessment of cognitive parameters by the
Morris water maze test
Animals were trained to swim to a visible platform in a
circular pool (180 cm in diameter and 60 cm in height)
located in a test room. In principle, rats can escape from
swimming by climbing onto the platform and over time the
rats apparently learn the spatial location of the platform
from any starting position at the circumference of the pool.
The pool was divided into four equal quadrants and filled
with water to a height of 40 cm. During the acquisition
phase, a movable circular platform (9 cm diameter) was
placed in one of the quadrants of the pool approximately
2 cm above the water level, and during the retention
phase, a similar platform was placed in the pool 2 cm below
the water level. The water was made opaque by adding a
nontoxic dye and four locations were equally spaced around
the edge of the pool (N, S, E, and W) and used as starting
points for the acquisition phase [4,20].
Figure 1 Flow chart of the experimental protocol. EPM Z elevated plus maze test; MWM Z Morris water maze test;
TL Z transfer latency.
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Animals received a training session consisting of four trials
with a gapof 5minutes between the two trials onDay 20. Four
different starting positions were used during all four trials. A
trial was started by releasing the animal into themaze facing
the wall of the pool and the latency to find the escape plat-
form was record to a maximum of 90 seconds. If the rat did
not escapeonto theplatformwithin 90 seconds, itwas guided
to the platform and was allowed to remain there for 20 sec-
onds. The time takenby the animal to reach the platformwas
considered as the initial acquisition latency [4,20].
2.5.2. Maze retention phase (testing for retention of
learned task)
Following training, the time taken tofind thehiddenplatform
(retention latency, RL)was assessed onDay 21 (24 hours after
the last training session) and Day 42. In brief, the animals
were released into the pool randomly at one of the edges
facing the wall of the pool and the time taken to reach the
platform was recorded. The change in RL from Day 21 to Day
42 was used to evaluate the learned skill or memory.
2.6. Elevated plus maze test (transfer latency)
Animals of different groups received their assigned drug
treatments (as mentioned previously) for 20 days. On Day
20, 1 hour after the assigned drug treatments, all animals
were tested on the elevated plus maze (EPM) for transfer
latency (TL). In brief, the animals were individually
placed at the end of the open arm facing away from
center of the maze and the time taken to enter the closed
arm was recorded and termed the TL. On Day 20, all an-
imals were allowed to explore the EPM for 90 seconds.
The animals remaining in the open arm without entering
into the closed arm within 90 seconds were gently pushed
into one of the enclosed arms and TL was recorded as 90
seconds (first trial); these animals were once again
allowed to explore the maze for another 10 seconds and
returned to their home cages after completion of the first
trial. Similarly, retention of memory was assessed as TL
on Day 21 (24 hours after the first trial) and Day 42 [4, 20].
2.7. Statistical analysis
All the values were expressed as mean  standard error of
the mean. The results were analyzed statistically usingANOVA followed by Tukey’s post hoc test. The minimum
level of significance was fixed at p < 0.05.
3. Results
3.1. Morris water maze test
Chronic oral administration of AlCl3 results in the deterio-
ration of learning and memory skills in Wistar rats, which is
supported by the literature reports cited in the present
study. Animals treated only with AlCl3 showed learning and
memory deficits in the Morris water maze task compared to
normal controls (p < 0.01). However, B. monniera (100 and
200 mg/kg; p < 0.05), rivastigmine (5 mg/kg; p < 0.05) and
a combination of B. monniera (100 mg/kg) and rivastigmine
(5 mg/kg; p < 0.01) offered treated groups significant
protection against AlCl3-induced learning and memory
deficits. Interestingly, the combination of B. monniera
(100 mg/kg) and rivastigmine (5 mg/kg) was found to be
therapeutically more potent than either treatment alone
against AlCl3-induced toxicity.
The results of the study are given in Fig. 2.
3.2. EPM test
The EPM test is the most commonly used method for eval-
uating memory skills in experimental animals. In the EPM,
memory was evaluated and expressed as TL. On Day 20, it
was found that chronic administration of AlCl3 significantly
increased TL in animals treated only with AlCl3 compared to
normal controls (p < 0.01), which indicates that the
memory deficits were due to AlCl3 administration. In
contrast to animals treated only with AlCl3, administration
of B. monniera, rivastigmine, and a combination of B.
monniera (100 mg/kg) and rivastigmine (5 mg/kg) allevi-
ated the AlCl3-induced learning and memory deficits in
Wistar rats. Exceptionally, the combination of B. monniera
(100 mg/kg) and rivastigmine (5 mg/kg) was highly potent
compared to either treatment alone (Fig. 3).
4. Discussion
Aluminum is one of the most abundantly found and
commonly used metals in the food industry, especially for
storage, packaging, and transportation [21]. Several studies
Figure 2 Evaluating the effect of Bacopa monniera (BM), rivastigmine (Riva), and their combination on memory retention in rats
through the Morris water maze test. All values are expressed as mean  standard error of the mean; means of various groups were
statistically compared by ANOVA followed by Tukey’s test using Graph Pad version 4.0. *p < 0.05 and yp < 0.01 compared to normal
controls; zp < 0.05 compared to rivastigmine 5 mg/kg; xp < 0.01 compared to controls; jjp < 0.05, {p < 0.01 compared to AlCl3;
zp < 0.05 compare to rivastigmine 5 mg/kg.
Synergistic Effect of Bacopa monniera and rivastigmine 211have estimated that an adult will consume around
3e12 mg/day of aluminum either directly or indirectly [22].
Long-term consumption of aluminum leads to its accumu-
lation in the brain, bone, muscle, kidney, and other organs,
resulting in the development of neurodegenerative disor-
ders [23,24], amyotrophic lateral sclerosis [25], encepha-
lopathy due to chronic renal failure [25,26], osteomalacia
[27], immunosuppression [28], and so on.
Aluminum is a potent pro-oxidant [29] and cholinotoxin
[30], and is considered to be one of the environmental
factors causing neurodegenerative disorders such as AD
[31]. While aluminum is not a transition metal and does not
directly initiate lipid peroxidation, it will potentiate the
oxidative damage caused by iron under acidic and neutral
conditions [32]. Also AlCl3 causes effective alteration of the
central nervous system, bloodebrain barrier, and central
cholinergic system. It may also decrease acetylcholine
levels in the hippocampal area, which leads to the devel-
opment of cognitive disorders such as AD, a decrease in
spatial learning, and memory disorders [19]. The brain isFigure 3 Evaluating the effect of Bacopa monniera (BM), rivastig
through the elevated plus maze test. All values are expressed as me
statistically compared by ANOVA followed by Tukey’s test using Grap
controls; zp < 0.05 compared to rivastigmine 5 mg/kg; xp < 0.01 ccovered with a thick lipid structure and has low antioxidant
defense associated with high oxygen metabolism (it
metabolizes about 20% of the total oxygen consumed by
the body), making it highly vulnerable to oxidative
damage [21].
Agents that enhance cholinergic transmission or
decrease cholinesterase activity have proven useful in
treating AD. In this regard, rivastigmine with its anticho-
linesterase activity has been shown to be beneficial in
treating the symptoms of AD associated with learning def-
icits and dementia [33]. Similarly, B. monniera is also highly
effective in alleviating learning and memory deficits.
Furthermore, studies have reported that rivastigmine and
B. monniera are also useful in preventing AlCl3-induced
neuronal damage [33e35]. Considering the beneficial effect
of B. monniera and rivastigmine in treating the symptoms
of AD, this study is an attempt to explore the possible
drugedrug interaction of B. monniera and rivastigmine in
reversing AlCl3-induced learning deficits and dementia
relevant to AD.mine (Riva), and their combination on memory retention in rats
an  standard error of the mean; means of various groups were
h Pad version 4.0. *p < 0.05 and yp < 0.01 compared to normal
ompared to controls; jjp < 0.05, {p < 0.01 compared to AlCl3.
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administration of AlCl3 to experimental animals results in
the development of learning deficits and dementia
[36e38], and hence this is considered to be a suitable
model for evaluating the beneficial effect of B. monniera
and rivastigmine in experimental animals.
Consistent with the literature reports, chronic adminis-
tration of AlCl3 in this study caused functional disability in
learning and memory skills, which was tested by the Morris
water maze and EPM tasks. In short, spatial memory was
evaluated in the Morris water maze test and showed
decreased acquisition and retention latencies when the rats
were tested on Day 21 and Day 42 of the treatment. How-
ever, groups treated with rivastigmine (5 mg/kg), B. mon-
niera (100 and 200 mg/kg), and their combination showed
better acquisition and retention latencies compared to
groups treated only with AlCl3, indicating significant pro-
tection against AlCl3-induced deterioration in learning and
memory skills. Similarly, in the EPM task, animals treated
only with AlCl3 showed diminished exploration (to locate
the closed arm) and lack of retention (enhanced retention
latency), indicating impaired learning and memory skills. In
contrast, animals treated with rivastigmine (5 mg/kg), B.
monniera (100 and 200 mg/kg), and their combination
showed better learning and memory retention compared to
the groups treated only with AlCl3. Exceptionally, the
combination of rivastigmine (5 mg/kg) with B. monniera
(100 mg/kg) showed good results in both the Morris water
maze and EPM tasks compared to either treatment alone.
Furthermore, in earlier studies B. monniera has been shown
to be effective in enhancing memory and learning skills [39]
and the phytoconstituents, bacoside A and bacoside B, are
thought to be responsible for its beneficial effect in treat-
ing memory and learning deficits. In exploring the under-
lying mechanism, a study conducted by Jyoti et al [35] on
the beneficial effect of B. monniera against AlCl3-induced
neurotoxicity, reported that B. monniera through its potent
antioxidant mechanism prevents AlCl3-induced neurotox-
icity in the brain, enhances neurogenesis and synaptic
cholinergic neurotransmission in regions such as the cere-
bral cortex and hippocampus, and is thus useful as an
antidementia drug during oxidative insults [19]. In exam-
ining the mechanism behind the synergistic effect of B.
monniera and rivastigmine, it can be concluded that B.
monniera (through its antioxidant mechanism) and riva-
stigmine (through its inhibitor anticholinesterase activity)
act through dual mechanisms to prevent neuronal damage
and/or enhance cholinergic neurotransmission, thereby
showing better therapeutic effect compared to either
treatment alone.5. Conclusion
The findings of the present study suggest that B. monniera
(100 and 200 mg/kg), rivastigmine (5 mg/kg), and a com-
bination of B. monniera and rivastigmine could be highly
beneficial in preventing the learning and memory impair-
ment induced by chronic administration of AlCl3. However,
the combination of B. monniera (Bacopa) with rivastigmine
was found to be more effective than either treatment alone
in preventing AlCl3-induced learning and memory deficits.Conflict of interest
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